← Back to Search

Virus Therapy

Avaxim Pediatric® for Autoimmune Rheumatic Disease

N/A
Waitlist Available
Led By Heinrike Schmeling, MD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Written informed consent provided for the subject by a parent or legal guardian.
Written informed assent from the participants themselves.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 to 7 months
Awards & highlights

Study Summary

This trial is comparing the immune response in immunosuppressed pediatric rheumatology patients to two different doses of Hepatitis A vaccine.

Eligible Conditions
  • Autoimmune Rheumatic Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 to 7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 to 7 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hepatitis A antibodies titre

Trial Design

2Treatment groups
Active Control
Group I: Avaxim Pediatric®Active Control1 Intervention
2 doses (0.5 mL each) six months apart of Avaxim Pediatric®
Group II: Avaxim ® (adult)Active Control1 Intervention
2 doses (0.5 mL each) six months apart of Avaxim ® (adult)

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
780 Previous Clinical Trials
841,709 Total Patients Enrolled
Heinrike Schmeling, MDPrincipal InvestigatorUniversity of Calgary
1 Previous Clinical Trials
1,238 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025